Is BPC-157 legal now? The FDA compounding vote, what it means for KPV and TB-500, and why Europe has none
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8-6, with one abstention, to recommend adding BPC-157 to the 503A Bulks List. That is the news. It is not the same thing as "BPC-157 is now legal." Here is what actually changed, and what did not.
What the committee actually voted on
The PCAC spent two days, July 23 to 24, reviewing seven candidate compounds for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-C, emideltide, epitalon, and semax. BPC-157 was evaluated specifically for ulcerative colitis. The vote passed narrowly, 8 in favor, 6 against, 1 abstention.
The 503A Bulks List is the mechanism that lets a licensed 503A compounding pharmacy prepare a substance for an individual patient's prescription when it has no FDA-approved drug product or USP/NF monograph of its own. Getting nominated is a step toward a legal, prescription-based compounding pathway. It is not a supplement-aisle green light, and it is not FDA drug approval.
It was not just BPC-157
The same session cleared more than one compound, which is why this vote matters beyond a single peptide. KPV and TB-500 also cleared alongside BPC-157, and MOTS-C passed the same two-day session on a separate 7-5 vote with two abstentions. None of it is final; FDA still has to act on each recommendation. But it is the first time any of these compounds has cleared a formal US regulatory review with an actual path to prescription-based, pharmacy-grade compounding.
Why FDA's own staff said no
The yes vote happened over the agency's own objection, and that objection is the most useful part of the story. FDA staff recommended against listing BPC-157, citing a lack of evidence for effectiveness in ulcerative colitis and a thin safety file: three adverse event reports on record, covering injection-site reactions and shortness of breath. One committee member called the peptide "not well-characterized," and several no-votes worried a Bulks List listing would read to consumers as an FDA safety stamp the data has not earned.
"Not well-characterized" is not a vibes critique. It means the agency still does not think there is a clean, widely accepted standard for what a quality-controlled BPC-157 product should look like. For a peptide already circulating heavily in gray-market channels, that is not a side issue, it is one of the main ones. The 8-6 split is the tell: that is not the pattern you get when a compound has a settled clinical case behind it.
Why that matters even if you already use BPC-157
The community tends to compress BPC-157 into a simple narrative: lots of people use it, lots of people swear by it, so the regulatory system is just late. The problem is that usage and clarity are not the same thing. The evidence base is thin. Research is almost entirely rodent work out of one lab (Sikiric, Zagreb, early 1990s), the human ulcerative-colitis data is small Phase 1/2 rectal-enema trials, and the community-standard dose of 100 to 200 mcg/day comes from vial sizing and vendor convention, not a clinical trial. The self-experimentation volume is high, but the attribution quality is poor. When something goes wrong, an injection-site reaction, shortness of breath, or a compound that simply does not do what the buyer expected, there is still no durable framework separating product failure, protocol failure, and molecule failure. Demand is already here; the interpretability layer is still weak. The vote does not change any of that math. BPC-157 is still investigational.
What changes right now: nothing, yet
The vote is a recommendation, not a rule. FDA makes the final call on whether BPC-157 actually lands on the Bulks List, and that decision is still pending. FDA follows PCAC recommendations most of the time, but it is not obligated to, and it has gone the other way before.
Until FDA acts, nothing about where you can legally get BPC-157 has changed. It has been off the FDA's do-not-compound list since April 2026 but still not on the compoundable list, which is why some prescribers currently write it as PDA (pentadecapeptide arginate, the di-arginine salt of the same molecule) as a legal workaround. The gray market, estimated at 5 to 10 billion dollars a year in US peptide spend, remains where most buyers are sourcing it today.
What changes if FDA finalizes it
If FDA accepts the recommendation, licensed 503A compounding pharmacies could prepare and dispense BPC-157 against a prescription. That is a real upgrade in the trust hierarchy: pharmacy-grade sourcing sits well above gray-market vendors on batch testing, quality control, and legal recourse if something goes wrong. It still is not full FDA drug approval. There is no clinical trial requirement attached, no efficacy bar beyond what the committee already called thin, and no guarantee that any given compounding pharmacy's BPC-157 is better-tested than what is already for sale today. For the pattern behind that gap, see why the FDA keeps shutting down good compounders first.
The US has a path. The EU has none.
The structural part is worth sitting with: the US now has a single federal process, run by one committee, that can put a compound on a nationwide compounding pathway. Whatever FDA decides applies in all 50 states.
Europe has nothing like it. No pending vote, no scheduled review, no committee working the question. There is no EU version of the PCAC. The European Medicines Agency approves medicines; it does not run a compounding-substance review like this one. Pharmacy compounding in the EU is a national competency, not an EMA one, which is why BPC-157, TB-500, and comparable peptides sit as research-use-only in most member states with no EU-wide legal channel. A Dutch pharmacy can prepare a peptide under a magistral-formula exemption; that exemption does not travel to France, where the regulator treats the same shipment very differently. There are 27 member states and 27 separate rulebooks, and no single body with the authority to do what the PCAC just did in one meeting.
Retatrutide is the sharpest version of this gap. It remains investigational in the EU with no EMA authorization, and the expected timeline for an EMA decision is 2027 to 2028. The US already has approved GLP-1s on the market and a compounding committee actively working the recovery-and-longevity peptide stack. For a buyer in the EU today, though, nothing has moved: research-use-only labeling and fragmented national enforcement, exactly as our country-by-country EU legality breakdown already covers. The present has not changed. The trajectory has.
How to think about sourcing while this is pending
None of this changes the vetting math. If you are buying BPC-157 now, treat it exactly as carefully as you did last week: ask for a real, batch-specific certificate of analysis, not a generic one, and do not read a committee vote as a safety signal it is not. A PCAC recommendation is not a safety stamp, and it has no bearing on legality for EU buyers. Our how-to-vet checklist covers what an actual COA needs to show, and if you are already running BPC-157, here is how to attribute a side effect. More on sourcing and the rest of the peptide landscape on the Ouros Lab blog.
FAQ
Is BPC-157 legal now?
No. The FDA's advisory committee voted to recommend it for the 503A Bulks List, but the FDA has not made a final decision. Until FDA acts, BPC-157's regulatory status is unchanged from before the vote.
What is the 503A Bulks List?
It is the list of substances licensed 503A compounding pharmacies can prepare for an individual patient's prescription when there is no FDA-approved product or USP monograph covering it. Being nominated is not the same as being FDA-approved.
Did KPV and TB-500 clear too?
Yes. KPV and TB-500 cleared alongside BPC-157 in the same session, and MOTS-C passed on a separate 7-5 vote. All of it is still a recommendation pending final FDA action, not a finished rule.
Does this mean BPC-157 is safer than before?
No. FDA's own staff flagged weak effectiveness data and only three adverse event reports on file, and said the substance is not well-characterized. The vote is a regulatory access question, not a new safety finding.
Is BPC-157 legal in Europe now?
No. The July 2026 PCAC vote is a US regulatory action with no EU counterpart. BPC-157 still has no EMA authorization and remains research-use-only across EU member states, with enforcement handled country by country.
Will BPC-157 disappear from the gray market if this passes?
Not immediately. Even with a legal compounding pathway open, price and prescription-access friction mean gray-market sourcing is likely to persist, the same pattern seen with other 503A-eligible peptides.